NYSEAMERICAN:NBY - NovaBay Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.74
▼ -0.005 (-0.68%)
1 month | 3 months | 12 months
Get New NovaBay Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NovaBay Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.74.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in NovaBay Pharmaceuticals. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
9/18/2019LADENBURG THALM/SH SHInitiated CoverageBuy$1.10
i
3/13/2019HC WainwrightDowngradeBuy ➝ Neutral
i
Rating by R. Selvaraju at HC Wainwright
3/13/2019LaidlawDowngradeBuy ➝ Hold
i
1/11/2019HC WainwrightSet Price TargetBuy$2.00
i
Rating by Ram Selvaraju at HC Wainwright
11/15/2018HC WainwrightSet Price TargetBuy$3.00
i
Rating by Ram Selvaraju at HC Wainwright
8/8/2018HC WainwrightSet Price TargetBuy$4.00
i
Rating by Ram Selvaraju at HC Wainwright
7/6/2018HC WainwrightSet Price TargetBuy$4.00
i
Rating by Ram Selvaraju at HC Wainwright
5/11/2018HC WainwrightSet Price TargetBuy$5.00
i
Rating by Ram Selvaraju at HC Wainwright
3/26/2018Roth CapitalDowngradeBuy ➝ Neutral
i
Rating by S. Henry at Roth Capital
3/21/2018HC WainwrightSet Price TargetBuy$6.00
i
Rating by Ram Selvaraju at HC Wainwright
11/15/2017LaidlawLower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
i
11/15/2017HC WainwrightSet Price TargetBuy$6.00
i
Rating by Ram Selvaraju at HC Wainwright
10/23/2017Roth CapitalSet Price TargetBuy$5.00
i
Rating by Scott Henry at Roth Capital
8/20/2017Roth CapitalSet Price TargetBuy$6.00
i
Rating by Scott Henry at Roth Capital
8/11/2017Maxim GroupReiterated RatingHold
i
Rating by Jason McCarthy at Maxim Group
8/11/2017HC WainwrightSet Price TargetBuy$6.00
i
Rating by Ram Selvaraju at HC Wainwright
6/20/2017Roth CapitalSet Price TargetBuy$6.00
i
Rating by Scott Henry at Roth Capital
6/5/2017Roth CapitalReiterated RatingBuy$5.50
i
Rating by S. Henry at Roth Capital
6/5/2017Roth CapitalInitiated CoverageBuy ➝ Buy$5.50
i
5/13/2017Maxim GroupReiterated RatingHold
i
Rating by Jason McCarthy at Maxim Group
3/27/2017Maxim GroupReiterated RatingHold
i
3/27/2017LaidlawInitiated CoverageBuy$10.00
i
3/26/2017HC WainwrightSet Price TargetBuy$6.00
i
Rating by Ram Selvaraju at HC Wainwright
3/24/2017Maxim GroupReiterated RatingHold
i
Rating by Lauren Chung at Maxim Group
2/6/2017Rodman & RenshawInitiated CoverageBuy$6.00
i
1/19/2017Maxim GroupReiterated RatingHold
i
Rating by Jason Kolbert at Maxim Group
10/6/2016Maxim GroupReiterated RatingHold
i
Rating by jason kolbert at Maxim Group
9/20/2016Maxim GroupReiterated RatingHold
i
Rating by jason kolbert at Maxim Group
5/14/2016Maxim GroupReiterated RatingHold
i
Rating by Jason Kolbert at Maxim Group
(Data available from 4/21/2016 forward)
NovaBay Pharmaceuticals logo
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $0.74
$0.72
$0.74

50 Day Range

MA: $0.66
$0.57
$0.73

52 Week Range

Now: $0.74
$0.52
$1.94

Volume

5,165 shs

Average Volume

4,725,391 shs

Market Capitalization

$30.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.5

Frequently Asked Questions

What sell-side analysts currently cover shares of NovaBay Pharmaceuticals?

The following sell-side analysts have issued research reports on NovaBay Pharmaceuticals in the last year: Zacks Investment Research.
View the latest analyst ratings for NBY.

What is the current price target for NovaBay Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for NovaBay Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NovaBay Pharmaceuticals in the next year.
View the latest price targets for NBY.

What is the current consensus analyst rating for NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NBY.

What other companies compete with NovaBay Pharmaceuticals?

How do I contact NovaBay Pharmaceuticals' investor relations team?

NovaBay Pharmaceuticals' physical mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company's listed phone number is +1-510-8998800 and its investor relations email address is [email protected] The official website for NovaBay Pharmaceuticals is novabay.com.